PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32166540-0	2020	Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.	Rivaroxaban	120-131	coagulation factor XII	Homo sapiens	65-71	
32166540-10	2020	In the peri-ablation study, increased F1 + 2 levels were associated with decline of C-Xa levels after periprocedural discontinuation of FXa inhibitors, which was greater in the rivaroxaban group than in the apixaban group.	Rivaroxaban	177-188	coagulation factor XII	Homo sapiens	38-44	
27796530-12	2017	Although trough level rivaroxaban suppresses F1 + 2 less than warfarin, the higher activities of protein C with rivaroxaban treatment compared to warfarin treatment may counterbalance this.	Rivaroxaban	22-33	coagulation factor XII	Homo sapiens	45-51	
28735423-8	2017	In contrast, D-dimer and prothrombin fragment F1+2 plasma levels indicated a higher activation of the coagulation cascade in apixaban/heparin than in rivaroxaban/heparin patients.	Rivaroxaban	150-161	coagulation factor XII	Homo sapiens	46-50	
26644369-12	2016	Rivaroxaban intake in the evening reduced morning F1+2 concentrations better at 8:00 AM than did administration on awakening (85 +- 25 nmol L(-1) vs. 106 +- 34 nmol L(-1) , CI: 9.4-32.1).	Rivaroxaban	0-11	coagulation factor XII	Homo sapiens	50-54